2023 Fall Clinical Virtual Grand Rounds
2023 Virtual Grand Rounds Session 9: June 14, 2023 - Topical Non-Steroidal Management of Atopic Dermatitis and Psoriasis: Clinical Insights for Dermatology Providers
About
To learn the right answer to the following question, click "Start Activity"
Tapinarof 1% and roflumilast 0.15% are currently undergoing clinical trials for atopic dermatitis. What were the endpoints that we found in the studies?
A) In INTEGUMENT-1 (roflumilast), 65% of patients achieved EASI 75 at the 2-week mark
B) In ADORING 1 (tapinarof), less than half the patients achieved an EASI 75 and a meaningful reduction in itch at the 8-week mark
C) In ADORING 1 (tapinarof), over half the patients achieved an EASI 75 and a meaningful reduction in itch at the 4 week mark
D) In INTEGUMENT-1 (roflumilast), 30% of patients achieved EASI 75 at the 2-week mark
This activity is supported by educational grants from Arcutis, Dermavant, and Incyte.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
June 15, 2023
June 15, 2024
Learning Objectives
At the completion of this activity, participants should be better able to:
Identify challenges associated with the use of topical corticosteroids in patients with atopic dermatitis (AD) and psoriasis
Review nonsteroid topical agents for the treatment of AD and psoriasis
Discuss clinical considerations for prescribing topical therapies to patients with AD and psoriasis
Intended Audience
Faculty
George Han, MD, PhD
Chief of Teledermatology
System Medical Director for Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Mona Shahriari, MD
Dermatologist, Yale University School of Medicine
Central CT Dermatology
Cromwell, CT
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: Celgene, Janssen, Lilly, MC2, Pfizer, UCB, Boehringer Ingelheim, Bond Avillion, Athenex, Amgen
Consultant: Janssen, Lilly, Abbvie, Sanofi Genzyme Regeneron, UCN, Boehringer Ingelheim, LEO, Ortho, Amgen, BMS
Speakers’ Bureau or Honoraria: Pfizer, Abbvie, Sanofi Genzyme Regeneron, SUN, Ortho
Grant/Research Support: AbbVie, Dermira, Cara, Dermavant, Novartis, Union
Consultant: Abbvie, BMS, Dermavant, Leo, Lilly, Sanofi, Regeneron, UCB
Speakers’ Bureau or Honoraria: Abbvie, BMS, Lilly, Leo, Janssen, Dermavant
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.